Urology Clinical Trials Update: Week 27, 2026

Published July 3, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

This Phase 3 trial is exploring a new treatment called cretostimogene grenadenorepvec for patients with intermediate risk non-muscle invasive bladder cancer after surgery. The goal is to reduce the chance that cancer will come back and provide a new option beyond regular monitoring. The study is enrolling 367 participants in the US and Canada, with results expected after full enrollment.

Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence

This Phase 4 study is comparing two treatments for women who have urgency urinary incontinence. It looks at an oral beta-agonist medication and injections of onabotulinumtoxinA to see which one better improves symptoms and patient satisfaction. The trial is recruiting in the United States and follows participants for up to 12 months to understand treatment effects over time.

Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine

This study tests a urine-based diagnostic tool called Cxbladder Triage Plus for adults who have small amounts of blood in their urine without visible symptoms. The aim is to help reduce the number of invasive cystoscopy procedures by better identifying who actually needs them. About 1000 participants are being recruited in the United States, with results expected after approximately nine months.

Augmentation Cystoplasty Using an Autologous Neo-Bladder Construct

This Phase 2 trial is testing a new surgical method using a patient’s own tissue to create a neo-bladder for people with fibrotic or contracted bladders. If successful, this approach could improve bladder function and reduce complications for those with this difficult condition. The study is recruiting a small group of 10 participants in the United States.

Colipral® (Probiotic Strain Escherichia Coli 5C (ECP24®)) for Prevention of Recurrent Cystitis in Menopausal Women

This upcoming study will evaluate a probiotic treatment called Colipral® aimed at preventing repeated urinary infections in menopausal women. It hopes to offer an alternative that reduces infection rates and the need for antibiotics. The trial is planned to last 24 weeks and is not yet recruiting participants.

This week saw important progress in trials focused on bladder cancer, urinary incontinence, and infection prevention. These studies represent ongoing efforts to improve treatment options and quality of life for patients with urologic conditions. More results are expected in the coming months that could influence how these conditions are managed.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.